Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News


Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report


Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31 March 2022.

Key highlights for the quarter included:

* Encouraging initial data for 2nd dose cohort of CHM 1101 (CLTX CAR T) phase 1 dose escalation study for patients with recurrent/progressive glioblastoma
* Initiated dosing of 1st patient in the 3rd dose cohort of CHM 1101 (CLTX CAR T) phase 1 dose escalation study for patients with recurrent/ progressive glioblastoma
* Strategic partnership with Be The Match BioTherapies to support Chimeric’s expanded clinical development of CHM 1101 through expedited collection, transport and delivery of cellular starting material and clinical drug products
* Final results of Phase 1 clinical trial of its CORE NK platform demonstrated an optimal safety profile and strong early signs of clinical benefit for patients
* CDH17 CAR T preclinical data featured as cover story for prestigious journal Nature Cancer
* Signed Sponsored Research Agreement with the University of Pennsylvania to support the continued research and development of CHM 2101 for preclinical studies in gastrointestinal cancers
* US patent and trademark office granted patent covering CLTX CAR technology used in CHM 1101 and CHM 1301
* Conducted non-renounceable entitlement offer and follow up shortfall placement to raise approximately $14.4 million (before costs)
* Chimeric appointed Kelly Thornburg to the position of Vice President, Head of Quality. Mr Thornburg has been advising the company as a consultant and will now serve in a leadership role to develop the Company’s quality systems and oversee all quality functions

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.